An innovative Biotech company About Us
First-in-class disease-modifying products Discover our science
Therapies for neurodegenerative & traumatic disorders Our Pipeline

Our vocation is to develop first-in-class innovative drugs to treat patients with degenerative or traumatic neurological disorders
with high unmet medical needs.

Our ambition is to improve the recovery of the functionality and the quality of life of patients.

Our Discovery

During embryogenesis, a small organ named Subcommisural Organ (SCO) located in the dorsal roof of the brain differentiates and secrets the SCO-spondin, a large multi-domain protein widely distributed in the CNS and with potent activity during neurogenesis.

Learn more

Our Products

Our products are first-in-class multi-target patented peptides with high potential in many CNS disorders, as demonstrated via distinctive and multifunctional mechanism of action on neural cells.

Learn more

Diseases focus

Neurological disorders are diseases of the central and peripheral nervous system. These disorders are of major clinical problems with high unmet medical needs and currently no satisfactory treatment.

Learn more


AD/PD 2022

Drs. Sighild Lemarchant and Mélissa Sourioux, Axoltis Pharma – Preclinical R&D department, will participate to AD/PD™2022, which will take place online and onsite March 15-20, 2022. Our exciting results about the mechanism of action and the targets engaged by our product NX210c, ensuring synaptic transmission and BBB integrity reinforcement, will … Read more

CTAD 2021

Dr Valérie Bourdès, Axoltis Pharma – Chief Medical Officer, will participate virtually to the Clinical Trials on Alzheimer’s Disease conference (CTAD) in … Read more

SFN 2021

Dr Sighild Lemarchant, Axoltis Pharma – PreClinical Project Manager, will participate to Neuroscience 2021, the Annual Meeting of Society for … Read more

ASIA 2021

Axoltis Pharma announces to attend the annual meeting of the American Spinal Injury Association (ASIA) on 8-10th July 2021 in … Read more